Q1

Q2

Q3

Interim Report 2026

Q4

QUALISYS

Q3 Interim Report 2026

Third quarter 2026 (July–September)

- Net sales amounted to SEK 46.1 million (54.3), corresponding to a decrease of 15.1 percent. (currency-adjusted -16.0 percent).
- Operating profit (EBIT) amounted to SEK 0.2 million (8.0).
- Net profit amounted to SEK 1.0 million (6.2).
- Earnings per share of SEK 0.10 (0.62).
- Cash flow from operating activities after investments amounted to SEK 5.4 million (-2.1).


First nine months of 2026 (January–September)

- Net sales amounted to SEK 140.5 million (169.0), corresponding to a decrease of 16.9 percent. (currency-adjusted -13.4 percent.
- Operating profit (EBIT) amounted to SEK 0.6 million (17.1).
- Net profit amounted to SEK 1.5 million (10.1).
- Earnings per share of SEK 0.15 (1.01).
- Cash flow from operating activities after investments amounted to SEK 8.1 million (4.7).

Key figures

	July–September			January–September			Full year
SEK million	**2026**	**2025**	**Change**	**2026**	**2025**	**Change**	**2025**
Net sales	46.1	54.3	-15.1%	140.5	169.0	-16.9%	269.0
Operating profit (EBIT)	0.2	8.0	-97.5%	0.6	17.1	-96.8%	50.3
Net profit	1.0	6.2	-83.4%	1.5	10.1	-85.3%	36.6
Earnings per share, SEK	0.10	0.62	-83.4%	0.15	1.01	-85.3%	3.66
Operating cash flow after investments	5.4	-2.1	359.4%	8.1	4.7	72.0%	19.6
Cash and cash equivalents	50.5	49.1		50.5	49.1		62.4

Net sales by region (July–September 2026)



Contents

Words from our CEO	4
Mission, Strategy and Business Model	5
Financials	10

Qualisys Holding AB (publ)
Corporate identity number 559002-6919

Photo:	**Page:**
© Johan Carlén	1,5,6

A Challenging Quarter, first OnTraq agreements

The third quarter marked an important milestone. Our markerless strategy moved from development into commercial reality. OnTraq signed its first agreements with elite clubs in both the Premier League and the NFL, and we pre-launched Prisma Pose for our installed base of biomechanics labs.

As announced in our preliminary results on 20 October, net sales were 46.1 MSEK (54.3), down 15.1%, or 16.0% currency adjusted, mainly due to orders being delayed. EBIT was 0.2 MSEK (8.0), reflecting both lower volumes and commercialising cost in markerless technology. For the first nine months, net sales were 140.5 MSEK (169.0) and EBIT 0.6 MSEK (17.1).

The underlying quality of our business remains strong. Gross margin improved to 72.2% (70.7), showing continued pricing power and an attractive product mix. Order intake was in line with the same period last year and followed our usual seasonal pattern.

Regional performance
Asia-Pacific continued to grow, up 10.7% to 11.0 MSEK (9.9). EMEA was stable at 19.0 MSEK (18.9) and was our largest region at 41% of sales, despite geopolitical uncertainty affecting orders in the Middle East. Americas declined to 16.1 MSEK (25.5), mainly because shifting US research funding priorities delayed Life Science orders, and some Engineering projects were postponed. Converting these projects into orders is our clear priority in the fourth quarter.

OnTraq: first signed agreements
In September, we secured the first OnTraq agreement with a major Premier League club, followed by an NFL team. We are now in final discussions with additional teams in Europe and North America.

OnTraq gives performance staff reliable data on player readiness and recovery, supporting decisions on training load and return to play without taking time away from training or matches. The subscription-based model adds recurring revenue that complements our project-based business and will make our revenue base more predictable over time.

Markerless: three routes to a growing market
In November we launched Prisma Pose, an add-on licence in QTM that brings markerless tracking into biomechanics labs' existing workflows. Strong interest from current customers makes this capital-light, high-margin revenue built on our installed base.

We now offer three ways into markerless capture. OnTraq serves elite sports, Prisma Pose serves biomechanics labs, and our partnership with Theia serves labs that need the highest validated accuracy. Together, they let us meet customer needs from the training ground to the clinic and the research lab.

Outlook
Although sales this quarter were below our expectations, we have taken a clear step forward in markerless, and both of our new products are already generating deals. OnTraq is a long-term investment in which we expect volumes to build gradually, while its subscription model adds stability over time.

The fourth quarter is historically our strongest, and our priorities are clear: convert delayed projects into orders, at the same time roll out Prisma Pose across our installed base, sign more OnTraq teams, and strengthen our position in selected engineering application areas.

Our financial targets over a business cycle are unchanged.

Ingemar Pettersson

"Our priorities are clear: convert delayed projects into orders, sign additional OnTraq teams and roll out Prisma Pose."





Mission, Strategy and Business Model

The Mission

"To be the world's preferred partner in creating performance-enhancing motion capture solutions, through technical excellence."

Life Science, Human Biomechanics

Advanced 3D Biomechanics Solutions by Qualisys

AT THE FOREFRONT of motion capture technology, Qualisys offers innovative solutions designed for the study and analysis of human movement. The precision, reliability, and adaptability of the solutions provide researchers worldwide with tools to better understand the complexities of human movement.

Examples of applications of Qualisys technology in this field include kinesiology, orthopedics, ergonomics, and gait analysis.

By providing high-quality measurement data and advanced analysis tools researchers can unlock new insights into human motion, ultimately contributing to innovation in health, movement sciences, and workplace safety.

More on Life Science, Human Biomechanics:
qualisys.com/life-sciences/human-biomechanics

Life Science, Sports Research

Enhanced Sports Performance Insights

WITHIN THE AREA of sports performance, motion capture is used to learn more about injury mechanisms and injury prevention methodology and to analyze a player's technique to optimize performance. The Qualisys system allows a deepened understanding of performance, safety, health, and long-term well-being that benefits athletes.

Qualisys marker-based motion capture technology that provides high-quality measurement data is the foundation of the company's sports performance and research solutions. This is a result of 35 years of constant development in close cooperation with the global research and healthcare communities.

More on Life Science, Sports Research:
qualisys.com/life-sciences/sports-research

Engineering

Precision Engineering Solutions for Diverse Environments and Industries

QUALISYS OFFERS a wide range of engineering solutions. In the maritime sector, organizations like naval research institutes, universities, and ocean energy facilities develop and study the movements of various vessels and objects, above and below water.

Additionally, Qualisys systems are well-suited for general industrial use. They provide high-precision ground truth positional and orientational data for the development of robotics, drones, autonomous vehicles, and other objects.

The benefits of the Qualisys system in these environments are the special camera packaging like weatherproofing (for outdoor use), underwater housing, and the possibility to capture in large volumes.

More on motion capture in engineering:
qualisys.com/engineering/robotics-and-uav

Entertainment


Motion Capture Solutions for Effortless Animation Workflows

QUALISYS PROVIDES the animation industry with highly accurate skeleton and object data that faithfully replicates actors' performances. The system ensures precise movement capture using markers. It seamlessly synchronizes with external equipment like video cameras, facial recording devices, and data gloves, enhancing the understanding of actor behavior and scene dynamics.


Real-time streaming to popular animation software and game engines enables a wide range of creative applications across various industries.

More on motion capture in entertainment:
qualisys.com/entertainment/animation

Business Idea, Strategy and Financial Objectives




Targets and Results



15%

Net Sales: Organic revenue growth shall be 15% per year over a business cycle.



20%

Operating margin: The EBIT margin is targeted to reach 20% annually over a business cycle.

Dividend policy: Qualisys primarily intends to reinvest cash flows into investments in profitable growth. Any excess liquidity is intended to be distributed to the shareholders.

QUALISYS' BUSINESS IDEA is to enable customers to efficiently analyze the motion of humans, animals, and objects through advanced motion capture systems, thereby contributing to fast and reliable research and development out-comes. By combining advanced hardware, intuitive software, and deep application expertise, the company delivers integrated, customized solutions that create measurable value across research, industry, and other advanced application areas.

QUALISYS' STRATEGY is to establish and strengthen its position as a global technology provider in motion capture by consistently prioritizing technical excellence, system integration, and application breadth. By scaling a common technology platform across multiple industries, the company creates the conditions for sustainable growth with strong profitability. Qualisys' strategy can be summarized in four focus areas:

1. **Technological leadership:** The company continuously invests in product development to consistently deliver products with high precision and reliable data quality. Integrated systems and long-term product development create high barriers to entry.

2. **Scalable growth through broad application:** Growth is driven by expanding the technology platform into new application areas and increasing usage across multiple industries. At the same time, customer relationships are deepened, and the international presence is strengthened in markets with high technological maturity.

3. **Business model:** The company offers customized system solutions that integrate hardware and software. Scalability is achieved through reuse of the technology platform, contributing to stable revenue and profitability. In the near future, project-based sales will also be complemented by subscription based revenue streams.

4. **Geographical reach:** The company invests in local presence and expertise to support regional growth and strengthen customer relationships in strategically important markets.

Our business model

Qualisys' customer offering mainly consists of complete solutions within 3D motion capture sold as a package solution for customers within the company's three segments Life Science, Engineering and Entertainment.


The majority of the business revenue is generated when delivering a complete system solution to the customer. The company´s overall solutions consists of a number of advanced high-speed cameras and customized software together with third-party solutions and accessories based on the customer´s needs.

FOR QUALISYS, IT IS CRUCIAL to find the best solution that match each individual customer's needs and therefore Qualisys works closely with customers throughout the course of the project. Depending on the type of movement and in which environment the customer intends to use the Qualisys' solution, the technical offer is adapted in close dialogue with the customer. This is vital to deliver the optimal technical solution to meet the customer's specific needs.


As a result of Qualisys' project-based business model, it is natural that net sales and operating profit (EBIT) are largely based on when customers place their orders and how long it takes to complete the order according to the customer's wishes. Because of this, Qualisys' net sales and operating profit (EBIT) can fluctuate relatively much from quarter to quarter depending on when orders are placed, and deliveries are carried out. The project's time frame varies as a result of several factors, including whether the customer is of a commercial or institutional nature and where in the world the customer is based, the system's intended application and the customer's construction of a facility where the system is to be used.

IT IS THE COMPANY'S OPINION that these fluctuations will continue to affect Qualisys' quarterly financial development, but that the trend will continue to be positive in accordance with the company's long-term financial goals.


Quarterly and TTM development of order intake




Quarterly and TTM development of net sales



Quarterly and TTM development of operating profit (Adjusted EBIT)



Qualisys Markerless Portfolio
-covering every need in sport, clinical & research




Prisma Pose

Meets biomechanics labs’ need for simplicity and speed - markerless tracking built right into QTM, one vendor, one workflow, no extra software to license or learn.



OnTraq

Meets elite sports teams' need for fast, scalable athlete monitoring - a dedicated end-to-end platform for baseline testing that fits directly into everyday training routines, no lab setup required.



Theia

Meets biomechanics labs' need for maximum validated accuracy - the industry's most peer-reviewed markerless engine, for labs where research-grade rigor matters more than workflow simplicity.



Financials

Financial overview

→ Third quarter 2026 (July–September)

Net sales

Net sales for the third quarter amounted to SEK 46.1 million (54.3), a decrease of 15.1 percent compared with the same period last year. Currency adjusted, net sales decreased by 16.0 percent.

The regional split of the sales for the quarter was 34.9 percent (47.0) Americas, 41.3 percent (34.8) EMEA and 23.8 percent (18.2) Asia-Pacific. The split per business segment was 61.3 percent (60.7) Life Science, 33.0 percent (38.2) Engineering and 5.7 percent (1.1) Entertainment.

Operating profit

The net sales had a gross margin of 72.2 percent compared with 70.7 percent for the same period last year. Total operating costs, excluding Cost of goods and Own development, were SEK –35.6 million, compared with SEK –33.2 million last year. The operating profit (EBIT) decreased compared with last year, mainly explained by the lower net sales, and was 0.4 percent (14.7 percent).

Financial net

The financial net was SEK 0.2 million (0.1).

Cash flow

During the third quarter, cash flow from operating activities amounted to SEK +6.4 million (0.6), with changes in working capital of SEK +5.8 million (–7.7).

Cash flow from investing activities amounted to SEK –1.0 million (–2.7), comprising investments in the development project concerning the so-called Markerless products.

Cash flow from financing activities amounted to SEK –1.7 million (–1.7), comprising amortization of lease liabilities.

Net cash flow for the quarter was SEK +3.7 million (–3.7).

→ January–September 2026

Net sales

Net sales for the first nine months of the year amounted to SEK 140.5 million (169.0), a decrease of 16.9 percent compared with the same period last year. Currency adjusted, net sales decreased by 13.4 percent.

The regional split of the sales for the period was 38.5 percent (40.2) Americas, 32.5 percent (33.8) EMEA and 28.9 percent (26.0) Asia-Pacific. The split per business segment was 63.7 percent (59.6) Life Science, 32.9 percent (38.4) Engineering and 3.4 percent (2.0) Entertainment.

Operating profit

The net sales had a gross margin of 68.9 percent compared with 68.5 percent for the same period last year. Total operating costs, excluding Cost of goods and Own development, were SEK –107.8 million, compared with SEK –111.3 million last year, whereof SEK 1.4 million IPO-related. The operating profit (EBIT) level decreased compared with last year and was 0.4 percent (10.1 percent), mainly explained by the lower net sales.

Financial net

The financial net was SEK 0.5 million (–3.1).

Cash flow

During the first nine months, cash flow from operating activities amounted to SEK +13.8 million (12.2), with changes in working capital of SEK +12.7 million (–5.1).

Cash flow from investing activities amounted to SEK –5.7 million (–7.5).

Cash flow from financing activities amounted to SEK –20.1 million (40.1), including a dividend of SEK –15.0 million.

Net cash flow for the period was SEK –12.0 million (44.8).

→ Financial position

As of September 30, 2026, the group's cash and cash equivalents amounted to SEK 50.5 million (49.1), equity to SEK 154.4 million (142.4) and the equity/assets ratio was 68.0 percent (63.9).

As of September 30, 2026, equity per share amounted to SEK 15.44 (14.24).

→ Parent company

The parent company, Qualisys Holding AB (publ.), has corporate identification no 559002-6919 and holds shares in subsidiaries.

The headquarters in Gothenburg operates through Qualisys AB, which leads all group-wide functions.

The Board of Directors operates from the Parent company.

The Parent company covers the administrative expenses for managing the Group and being a listed company.

As of September 30, 2026, the total assets amounted to SEK 86.1 million (82.8) and the equity to SEK 68.1 million (81.5).

→Condensed consolidated income statements

	July-September		January-September		Full year
SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Net sales	46,118	54,293	140,520	169,016	269,047
Other income	1,412	490	6,796	6,324	6,801
Total revenue	**47,530**	**54,783**	**147,316**	**175,340**	**275,848**
Own development	1,136	2,309	4,720	6,296	9,388
Cost of goods	-12,833	-15,916	-43,653	-53,228	-86,141
Other external expenses	-11,400	-10,602	-31,392	-35,647	-47,437
Personnel expenses	-20,437	-19,610	-64,625	-63,813	-85,163
Depreciation of tangible and intangible assets	-2,865	-2,454	-7,557	-7,044	-9,185
Other operating external expenses	-930	-517	-4,257	-4,844	-6,980
Total operating costs	**-47,328**	**-46,790**	**-146,765**	**-158,280**	**-225,518**
Operating profit (EBIT)	**201**	**7,993**	**552**	**17,060**	**50,330**
Financial income	482	385	1,881	1,383	1,762
Financial costs	-252	-320	-1,385	-4,477	-4,867
Profit after financial items	**432**	**8,058**	**1,048**	**13,966**	**47,226**
Taxes	587	-1,901	445	-3,825	-10,603
Net profit	**1,019**	**6,157**	**1,493**	**10,141**	**36,623**
Attributable to					
Parent company shareholders	1,019	6,157	1,493	10,141	36,623
Average number of shares	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Earnings per share, SEK	0.10	0.62	0.15	1.01	3.66

Consolidated statement of income and other comprehensive income

	July-September		January-September		Full year
SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Net profit	**1,019**	**6,157**	**1,493**	**10,141**	**36,623**
Other comprehensive income					
Items that have been or can be reclassified to net profit					
Translation difference on translation of foreign operations	367	-178	-129	-1,783	-2,637
Total comprehensive income for the period	**1,386**	**5,979**	**1,364**	**8,358**	**33,986**
Comprehensive income attributable to					
Parent company shareholders	1,386	5,979	1,364	8,358	33,986

Condensed consolidated statement of financial position

SEK thousands	September 30 2026	September 30 2025	December 31 2025
ASSETS			
Non-current assets			
Capitalized development expenses and similar items	31,914	26,141	29,145
Goodwill	30,546	30,532	30,532
Property, plant and equipment, right-of-use	20,057	26,883	25,169
Equipment, owned	3,274	2,697	3,297
Deferred tax assets	989	451	321
Other financial non-current assets	91	58	86
Total non-current assets	**86,871**	**86,762**	**88,550**
Current assets			
Inventories	26,956	32,452	23,983
Tax assets	10,965	5,143	2,575
Trade receivables	43,627	43,064	68,419
Other current receivables	2,762	2,425	3,915
Prepaid expenses and accrued income	5,472	4,089	3,566
Cash and cash equivalents	50,456	49,112	62,406
Total current assets	**140,238**	**136,285**	**164,863**
TOTAL ASSETS	**227,109**	**223,047**	**253,413**

SEK thousands	September 30 2026	September 30 2025	December 31 2025
EQUITY AND LIABILITIES			
Equity attributable to shareholder of the Parent Company			
Share capital	500	500	500
Other reserves	-1,609	-626	-1,480
Retained earnings	155,530	142,558	169,037
Total equity	**154,421**	**142,432**	**168,057**
Non-current liabilities			
Other non-current liabilities	1,286	1,977	1,977
Non-current lease liabilities	11,225	19,670	18,047
Deferred tax liabilities	12,191	10,007	12,252
Total non-current liabilities	**24,702**	**31,654**	**32,276**
Current liabilities			
Trade payables	10,860	11,831	15,460
Advance payments from customers	2,652	3,752	486
Current lease liabilities	8,104	6,459	6,445
Tax liabilities	-	101	-
Other liabilities	8,306	5,534	10,151
Accrued expenses and deferred income	18,064	21,284	20,538
Total current liabilities	**47,986**	**48,961**	**53,080**
Total liabilities	**72,688**	**80,615**	**85,356**
TOTAL EQUITY AND LIABILITIES	**227,109**	**223,047**	**253,413**

Consolidated changes in equity

	Attributable to parent company shareholders			
SEK thousands	**Share capital**	**Other reserves**	**Profit and loss carried forward, incl. profit for the period**	**Total equity**
Opening balance January 1, 2025	**500**	**1,157**	**162,068**	**163,725**
Profit for the period January-September 2025			10,141	10,141
Other comprehensive income for the period		-1,783		-1,783
Warrant program			349	349
Dividend to shareholders of the Parent Company			-30,000	-30,000
Closing balance September 30, 2025	**500**	**-626**	**142,558**	**142,432**
Profit for the period October-December 2025			26,479	26,479
Other comprehensive income for the period		-854		-854
Closing balance December 31, 2025	**500**	**-1,480**	**169,037**	**168,057**
Opening balance January 1, 2026	**500**	**-1,480**	**169,037**	**168,057**
Profit for the period January-September 2026			1,493	1,493
Other comprehensive income for the period		-129		-129
Dividend to shareholders of the Parent Company			-15,000	-15,000
Closing balance September 30, 2026	**500**	**-1,609**	**155,530**	**154,421**

Condensed consolidated cash flow statement

	July - September		January - September		Full Year
SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Operating profit	201	7,993	552	17,060	50,330
Adjustments for non-cash items	2,780	2,456	7,738	7,045	9,187
Interest paid/ received	-	65	-	64	53
Tax paid	-2,404	-2,246	-7,213	-6,834	-10,568
Cash flow from operating activities before changes in working capital	**577**	**8,268**	**1,077**	**17,335**	**49,001**
Changes in working capital					
Increase (-)/Decrease (+) in inventories	191	-2,760	-3,040	-6,353	2,142
Increase (-)/Decrease (+) in operating receivables	11,440	-1,270	22,140	5,545	-14,528
Increase (+)/Decrease (-) in operating liabilities	-5,819	-3,639	-6,377	-4,331	-5,586
Cash flow from changes in working capital	**5,812**	**-7,669**	**12,723**	**-5,139**	**-17,971**
Cash flow from operating activities	**6,389**	**599**	**13,800**	**12,196**	**31,030**
Investing activities					
Investments in tangible fixed assets	108	-341	-967	-1,074	-1,781
Investments in intangible assets	-1,136	-2,325	-4,720	-6,406	-9,564
Investments in subsidiary	-	-	-	-	-109
Cash flow from investing activities	**-1,028**	**-2,666**	**-5,687**	**-7,480**	**-11,454**
Financing activities					
Dividend	-	-	-15,000	-30,000	-30,000
Change in current receivables to parent company	-	-	-	74,685	74,685
Warrants	-	-	-	349	349
Amortization liabilities to parent company	-	-	-	-	-
Amortization of lease liabilities	-1,701	-1,661	-5,126	-4,956	-6,592
Cash flow from financing activities	**-1,701**	**-1,661**	**-20,126**	**40,078**	**38,442**
Cash flow for the period	**3,660**	**-3,728**	**-12,013**	**44,794**	**58,018**
Opening cash and cash equivalents	46,898	53,265	62,406	5,025	5,025
Exchange-rate difference in cash and cash equivalents	-102	-425	63	-707	-635
Closing cash and cash equivalents	**50,456**	**49,112**	**50,456**	**49,112**	**62,406**

Parent company condensed income statements

	July-September		January-September		Full year
SEK thousands	**2026**	**2025**	**2026**	**2025**	**2025**
Net sales	-	-	-	-	-
Group Sales	35	-	266	-	-
Total revenue	**35**	**-**	**266**	**-**	**-**
Other external expenses	-944	-362	-2,431	-3,452	-3,763
Personnel expenses	-436	-348	-1,123	-715	-556
Total operating costs	**-1,380**	**-710**	**-3,554**	**-4,167**	**-4,319**
Operating profit (EBIT)	**-1,345**	**-710**	**-3,288**	**-4,167**	**-4,319**
Profit from shares in group companies	-	30,000	-	30,000	30,000
Financial income	-	1	-	11	13
Financial costs	-	-	-	-3,166	-3,166
Profit after financial items	**-1,345**	**29,291**	**-3,288**	**22,678**	**22,528**
Appropriations	-	-	-	-	4,350
Profit before tax	**-1,345**	**29,291**	**-3,288**	**22,678**	**26,878**
Taxes	677	-	677	-	-8
Net profit	**-668**	**29,291**	**-2,611**	**22,678**	**26,870**

Because the parent company has no items to report under Other comprehensive income, no statement of comprehensive income has been prepared.

Parent company condensed balance sheet

SEK thousands	September 30 2026	2025	December 31 2025
ASSETS			
Non-current assets			
Participations in group companies	80,580	80,580	80,580
Deferred tax assets	677	-	-
Other financial non-current assets	-	-	-
Total non-current assets	**81,257**	**80,580**	**80,580**
Current assets			
Tax assets	5	-	91
Current receivables from group company	2,870	1,451	5,301
Other current receivables	93	38	1
Prepaid expenses and accrued income	1,735	216	35
Cash and cash equivalents	119	471	413
Total current assets	**4,822**	**2,176**	**5,841**
TOTAL ASSETS	**86,079**	**82,756**	**86,421**

SEK thousands	September 30 2026	2025	December 31 2025
EQUITY AND LIABILITIES			
Equity	**68,116**	**81,535**	**85,727**
Current liabilities to group company	15,000	-	-
Trade payables	502	70	70
Tax liabilities	-	3	-
Accrued expenses and deferred income	2,460	1,148	624
Total liabilities	**17,963**	**1,221**	**694**
TOTAL EQUITY AND LIABILITIES	**86,079**	**82,756**	**86,421**

Key figures, group

	July-September		January-September		Full year
	2026	**2025**	**2026**	**2025**	**2025**
Net sales, SEK million	46.1	54.3	140.5	169.0	269.0
Gross margin %	72.2	70.7	68.9	68.5	68.0
EBITDA %	6.6	19.2	5.8	14.3	22.1
EBIT %	0.4	14.7	0.4	10.1	18.7
Adjusted EBIT, SEK million	0.2	8.0	0.6	18.5	51.7
Adjusted EBIT %	0.4	14.7	0.4	10.9	19.2
Equity/ assets ratio %	68.0	63.9	68.0	63.9	66.3
Cash conversion %	174.8	1.1	100.0	47.7	50.6
Dividend per share, SEK	-	-	1.50	3.00	3.00
Shares outstanding at end of period before dilution	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Shares outstanding at end of period after dilution	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Average shares outstanding before dilution	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Average shares outstanding after dilution	10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Equity per share before and after dilution, SEK	15.44	14.24	15.44	14.24	16.81
TTM, Return on equity %	18.8	22.9	18.8	22.9	23.7
TTM, Net sales, SEK million	240.6	258.7	240.6	258.7	269.0
TTM, Order intake, SEK million	234.8	243.4	234.8	243.4	240.0
TTM, Adjusted EBIT %	14.1	18.6	14.1	18.6	19.2
Net debt (+)/ cash (-) excluding IFRS 16	-50.5	-49.1	-50.5	-49.1	-62.4
Employed at end of period	83	80	83	80	83

Adjusted EBIT excludes IPO-related costs of SEK 1.4 million recognised in the first half of 2025 (SEK 1.4 million for the full year 2025). Reported EBIT for January–September 2025 was SEK 17.1 million.

Definitions of key figures

Key figures according to IFRS	Definition	Reason for use
Operating profit (EBIT)	Earnings before interest and tax.	Used as an indicator that shows the Group's ability to make a profit, regardless of the financing structure and tax rate.
Operating margin (EBIT) %	Operating profit as a percentage of net sales.	Over time, this key figure conveys a deeper understanding of the company's profitability.
Equity/ total assets %	Total equity divided by total value of assets.	This key figure shows how much of the business that is financed by itself.
Average number of shares	The weighted average number of shares outstanding during the period, before and after dilution.	The weighted average number of shares outstanding is used for different key ratios.
Earnings per share	Net profit divided by average number of shares.	For a shareholder, this key figure can be compared with equivalent value for other listed companies.

Qualisys Group presents certain measures that are not defined under IFRS (alternative performance measures - "APMs"). These are used by management to assess the financial and operational performance of the Group. Management believes that these APMs provide useful information regarding the Group's financial and operating performance. Such measures may not be comparable to similar measures presented by other companies. The APMs have been derived from the Group's internal reporting and are not audited.

Alternative Performance Measures	Definition	Reason for use
Gross margin	Earnings after deduction of costs for direct material and services.	Used as an indicator that shows the Group's underlying ability to make a profit in its business before expenses.
Gross margin %	Gross margin as a percentage of net sales.	A measure that indicates ability to make profit in its business before expenses.
Adjusted operating profit (adj EBIT)	Earnings before interest and tax adjusted for non-recurring items	Used as an indicator that shows the Group's ability to make a profit without non-recurring items, regardless of the financing structure and tax rate.
Adjusted operating (adj EBIT) margin %	Earnings before interest and tax adjusted for non-recurring items as a percentage of net sales.	Over time, this key figure conveys a deeper understanding of the company's profitability.

Alternative Performance Measures	Definition	Reason for use
Operating profit before depreciation and amortisation (EBITDA)	Earnings before depreciation and amortisation.	Used as an indicator that shows the Group's ability to make a profit, regardless of depreciation of assets as well as method of financing.
Operating margin before depreciation and amortisation (EBITDA) %	Earnings before depreciation and amortisation as a percentage of net sales.	A key internal measure, that provides users of financial statements with a better understanding of the Group's financial performance both short and long term.
Operating cash flow after investments	Cash flow from operating activities, after deduction of investing activities.	Used as an indicator that shows the ability to generate cash flow from its operation.
Cash conversion %	Operating cash flow in relation to EBITDA.	Used as an indicator of the ability to convert profit into cash flow.
Trailing 12 months (TTM) return on equity %	Net profit for past four quarters in relation to average equity (opening and closing balance for the same period, divided by two), in percentage.	The key figure shows the return on the shareholders' invested capital.
Trailing 12 months (TTM) net sales	Net sales for past four quarters.	Used as a figure to be compared with any balance sheet item.
Trailing 12 months (TTM) order intake	Order intake for past four quarters.	Used as a figure to be compared with TTM net sales to indicate sales trends.
Net debt/ net cash, excluding IFRS 16	Long-term interest bearing liabilities excluding lease liabilities deducted with available liquidity.	The key figure shows the interest bearing debts less available liquidity without lease liability (since lease liability has another due date structure).
Employed at end of period	Number of full-time employees and full-time consultants (assigned on a long-term base), at end of period.	A key figure to understand personnel and consultant expenses in a mid term perspective.

Notes

NOTE 1 Accounting principles

Qualisys Group applies International Financial Reporting Standards (IFRS) as adopted by the European Union. This report has been prepared in accordance with IAS 34, Interim Financial Reporting. The Group's interim reports contain a condensed set of financial statements. For the Group this means that the disclosures are limited compared to the annual report.

The accounting principles adopted in the preparation of this interim report apply to all periods and comply with the accounting principles presented in the Group's Annual Report 2025.

For the Parent Company financial statements in general are presented in condensed versions and with limited disclosures compared to the annual report. The most recent annual financial statements of Qualisys Holding AB (publ.) have been prepared in compliance with the Swedish Annual Accounts Act (1995:1554) and recommendation RFR2, Accounting for legal entities of the Swedish Financial Reporting Board.

IFRS 18 *Presentation and Disclosure in Financial Statements* replaces IAS 1 and applies from 1 January 2027. The standard mainly affects how the income statement is presented and what must be disclosed. It does not change how items are recognised or measured. Qualisys Group has not adopted IFRS 18 early. The Group considers itself prepared for the transition and does not expect a material impact on its financial reporting.

NOTE 2 Disaggregation of revenue

Qualisys sells products and services for precise motion measurements. Sales of products are revenue recognized at a point in time, when control of the products has been transferred.

Revenue from services related to installation of products, repairs or maintenance service is recognized when control is transferred over the time the service is provided. Development work is recognized as revenue as the work is carried out.

Geography is considered to be an important attribute when disaggregating the Group's revenue, see below.

Net sales per Geography	Third quarter July - September				First nine months January - September				Twelve months January - December	
SEK thousands	**2026**	**(%)**	**2025**	**(%)**	**2026**	**(%)**	**2025**	**(%)**	**2025**	**(%)**
EMEA	19,038	41.3%	18,885	34.8%	45,712	32.5%	57,201	33.8%	100,384	37.3%
Americas	16,108	34.9%	25,500	47.0%	54,144	38.5%	67,917	40.2%	99,305	36.9%
Asia-Pacific	10,972	23.8%	9,908	18.2%	40,664	28.9%	43,898	26.0%	69,358	25.8%
Total	**46,118**		**54,293**		**140,520**		**169,016**		**269,047**	

NOTE 3 Net Sales per Segment

Net sales per Segment	Third quarter July - September				First nine months January - September				Twelve months January - December	
SEK thousands	**2026**	**(%)**	**2025**	**(%)**	**2026**	**(%)**	**2025**	**(%)**	**2025**	**(%)**
Engineering	15,224	33.0%	20,748	38.2%	46,202	32.9%	64,913	38.4%	94,784	35.2%
Entertainment	2,642	5.7%	581	1.1%	4,815	3.4%	3,408	2.0%	6,005	2.2%
Life Science	28,252	61.3%	32,964	60.7%	89,503	63.7%	100,695	59.6%	168,258	62.5%
Total	**46,118**		**54,293**		**140,520**		**169,016**		**269,047**	

Risk and uncertainty factors

Qualisys works on an ongoing basis to identify, control and reduce risks in various systems and processes. Risk analysis of day-to-day operations is performed on an ongoing basis and in connection with major activities. The risk factors are described in the Annual Report and consist of operational risks, industry risks and financial risks.

Interim Report Q3 2026

Other disclosures

Organization and personnel
At the end of the period, there were 83 (80) employed at full time, of whom 18 (16) were women and 65 (64) were men. Of these ~40% work with R&D.

Proposed appropriation of profits
The annual meeting on May 18, 2026 decided that a dividend of SEK 30 million be paid for 2025, that is SEK 3.00 (3.00) per share, distributed in two payments. The first tranche was paid in May and the second tranche will be paid on November 26, 2026.

Significant events after the balance sheet date
There have been no significant events to report.

Warrant program 2025/2028
There is one outstanding program with 51,700 warrants with ending time in June 2028. In this program, one warrant equals one share. The program is out-of-money hence there is currently no dilution.

Share information
The number of shares at the end of period amounts to 10,000,000, all with a quota value of SEK 0.05 and equal voting rights.


Assurance
This report has been subject to review by the company's auditors.

The CEO and the Board of directors provide their assurance that this interim report provides a fair overview of the company's operations, position, and earnings and describes any significant risks and uncertainties that the company may face.

Gothenburg, November 12, 2026
Qualisys Holding AB (publ)
CEO & Board of directors

Shareholders information

Ownership	Num. of shares	Capital/Votes (%)
Vätterledens Invest Aktiebolag	3,015,409	30.15
Ramhill AB	1,005,000	10.05
Avanza Pension	608,257	6.08
Investment AB Spiltan	576,000	5.76
Edastra AB	490,000	4.90
Swedbank Robur Funds	477,000	4.77
Second Swedish National Pension Fund	460,000	4.60
Måns Flodberg	450,000	4.50
Handelsbanken Funds	250,000	2.50
Knutsson Holdings AB	157,895	1.58
Total Top 10	**7,489,561**	**74.90**
Others	2,510,439	25.10
Total number of shares	**10,000,000**	100.00



Financial reports:
Interim reports and other financial reports are available at investors.qualisys.com

Stock market and Certified Advisor:
Shares in Qualisys Holding AB (publ) have been traded on Nasdaq First North Premier Growth Market since February 21, 2025. The company's Certified Advisor is Svensk Kapitalmarknadsgranskning AB.

Please address any questions to:
Ingemar Pettersson, CEO
Phone: +46 31 336 94 18
ingemar.pettersson@qualisys.se

Magnus Holm, CFO
Phone: +46 70 974 45 93
magnus.holm@qualisys.com

Financial calendar
2026 Q3
November 12, 2026.

Year-end report 2026
February 24, 2027

2027 Q1
May 11, 2027

2027 AGM
May 17, 2027

2027 Q2
July 29, 2027

2027 Q3
November 5, 2027

Year-end report 2027
February 23, 2028

This is information that Qualisys Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons above on November 12, 2026, at 8.30 a.m. (CET).

Offices

Qualisys Europe (Main office)
Qualisys AB / Qualisys Holding AB (publ)
Kvarnbergsgatan 2
411 05 Gothenburg
Sweden

Qualisys North America
Qualisys North America, Inc.
1603 Barclay Blvd
Buffalo Grove
Illinois 60089 USA

Qualisys Asia Pacific
Qualisys APAC PTE. LTD.
23 New Industrial Road
04-08 Solstice Business Center
536209 Singapore

Qualisys China
Qualisys China
Room 368, Section 302
No. 211 Fute North Road
Shanghai PRC, 200131

Qualisys India
Qualisys Motion Capture
India Private Limited
Unit No.704,
K.M. Trade Tower,
Modipon Vihar, Kaushambi,
Ghaziabad, Uttar Pradesh,
India-201010

Contact

Phone: +46 31 336 94 00

Email: investorrelations@qualisys.com